search
Back to results

Safety and Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain With an Open-label Extension

Primary Purpose

Pain, Postoperative, Bunion

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
COV795
Placebo
Sponsored by
Mallinckrodt
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain, Postoperative focused on measuring Moderate Post-Operative Pain, Severe Post-Operative Pain, Bunionectomy

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria

  1. Complete the informed consent process as documented by signed informed consent form(s).
  2. Be in generally good health.
  3. Be 18 to 75 years of age, inclusively at the time of screening.
  4. Be scheduled for a primary unilateral first metatarsal bunionectomy (with no collateral procedures).
  5. Have a body mass index ≤33 kg/m2.
  6. Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant for the duration of the study, surgically sterile or at least two years postmenopausal, or practicing an acceptable form of birth control for at least 2 months
  7. Male subjects must be sterile or commit to the use of a reliable method of birth control
  8. Be classified as Physical status 1 (PS-1) to PS-2 by the American Society of Anesthetists (ASA) Physical Status Classification System.
  9. Be willing to complete the pain evaluations and return to the clinic as scheduled.

Exclusion Criteria

  1. Have an uncontrolled medical condition, serious intercurrent illness, clinically significant general health condition, or extenuating circumstance that may significantly decrease study compliance or otherwise preclude their participation in the study.
  2. Have a clinically significant abnormal electrocardiogram (ECG) at screening
  3. Have had any type of gastric bypass surgery or have a gastric band.
  4. Have previous abdominal surgery within the past year or history of abdominal adhesions, known or suspected paralytic ileus.
  5. Have a history of any medical condition that would alter the absorption, distribution, metabolism or excretion of COV795
  6. Have a history of severe bronchial asthma, hypercarbia, or hypoxia
  7. Have a clinically significant abnormality on their clinical laboratory values
  8. Have Addison's disease, benign prostatic hyperplasia, or kidney disease
  9. Have donated blood or blood components within 3 months prior to the screening visit.
  10. Have a known allergy or hypersensitivity to any opioid analgesics, anesthetics, acetaminophen, Non-steroid anti-inflammatory drugs (NSAIDs).
  11. Have a history of intolerance to short term opioid use.
  12. Unwilling to discontinue certain prohibited medications within the allotted time before surgery and throughout the duration of the study. Have taken certain drugs within the indicated times before surgery.
  13. Have a history of substance or alcohol abuse and/or a positive result on drug screening.
  14. Have a positive test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) at the screening visit.
  15. Have dysphagia and/or cannot swallow study medication whole.
  16. Have a history of migraine or frequent headaches, seizures, or are currently taking anticonvulsants.
  17. Have previously participated in a clinical trial using COV795 or had a bunionectomy in the last 3 months.
  18. Received any investigational drugs or devices within 4 weeks prior to the screening visit.
  19. Other criteria as specified in the trial protocol.

Sites / Locations

  • Trovare Clinical Research, Inc.
  • Lotus Clinical Research, LLC
  • Chesapeake Research Group, LLC
  • Endeavor Clinical Trials, PA
  • Jean Brown Research, Inc.

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

COV795

Placebo

Arm Description

Outcomes

Primary Outcome Measures

SPID48 (Summed Pain Intensity Difference)
Pain intensity (PI) is measured using the 11-point (0-10) Numeric Pain Rating Scale (NPRS) score. PID is the arithmetic difference in NPRS score at the time point of interest from the baseline score. SPID48 is the sum of time-weighted PID scores measured 22 times over the 48 hour assessment period, with a total score ranging from -480 (worst) to 480 (best). A higher SPID value indicates greater pain relief.

Secondary Outcome Measures

Full Information

First Posted
November 28, 2011
Last Updated
September 8, 2016
Sponsor
Mallinckrodt
search

1. Study Identification

Unique Protocol Identification Number
NCT01484652
Brief Title
Safety and Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain With an Open-label Extension
Official Title
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Safety and Analgesic Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain Followed by an Open-Label Extension
Study Type
Interventional

2. Study Status

Record Verification Date
September 2016
Overall Recruitment Status
Completed
Study Start Date
November 2011 (undefined)
Primary Completion Date
August 2012 (Actual)
Study Completion Date
September 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mallinckrodt

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary objective of this study is to show the effectiveness of repeated doses of COV795 versus placebo, using the summed pain intensity difference over the first 48 hours in subjects with acute moderate to severe pain following bunionectomy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Postoperative, Bunion
Keywords
Moderate Post-Operative Pain, Severe Post-Operative Pain, Bunionectomy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
329 (Actual)

8. Arms, Groups, and Interventions

Arm Title
COV795
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
COV795
Other Intervention Name(s)
MNK795
Intervention Description
2 tablets taken every 12 hours
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
2 tablets taken every 12 hours
Primary Outcome Measure Information:
Title
SPID48 (Summed Pain Intensity Difference)
Description
Pain intensity (PI) is measured using the 11-point (0-10) Numeric Pain Rating Scale (NPRS) score. PID is the arithmetic difference in NPRS score at the time point of interest from the baseline score. SPID48 is the sum of time-weighted PID scores measured 22 times over the 48 hour assessment period, with a total score ranging from -480 (worst) to 480 (best). A higher SPID value indicates greater pain relief.
Time Frame
48 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Complete the informed consent process as documented by signed informed consent form(s). Be in generally good health. Be 18 to 75 years of age, inclusively at the time of screening. Be scheduled for a primary unilateral first metatarsal bunionectomy (with no collateral procedures). Have a body mass index ≤33 kg/m2. Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant for the duration of the study, surgically sterile or at least two years postmenopausal, or practicing an acceptable form of birth control for at least 2 months Male subjects must be sterile or commit to the use of a reliable method of birth control Be classified as Physical status 1 (PS-1) to PS-2 by the American Society of Anesthetists (ASA) Physical Status Classification System. Be willing to complete the pain evaluations and return to the clinic as scheduled. Exclusion Criteria Have an uncontrolled medical condition, serious intercurrent illness, clinically significant general health condition, or extenuating circumstance that may significantly decrease study compliance or otherwise preclude their participation in the study. Have a clinically significant abnormal electrocardiogram (ECG) at screening Have had any type of gastric bypass surgery or have a gastric band. Have previous abdominal surgery within the past year or history of abdominal adhesions, known or suspected paralytic ileus. Have a history of any medical condition that would alter the absorption, distribution, metabolism or excretion of COV795 Have a history of severe bronchial asthma, hypercarbia, or hypoxia Have a clinically significant abnormality on their clinical laboratory values Have Addison's disease, benign prostatic hyperplasia, or kidney disease Have donated blood or blood components within 3 months prior to the screening visit. Have a known allergy or hypersensitivity to any opioid analgesics, anesthetics, acetaminophen, Non-steroid anti-inflammatory drugs (NSAIDs). Have a history of intolerance to short term opioid use. Unwilling to discontinue certain prohibited medications within the allotted time before surgery and throughout the duration of the study. Have taken certain drugs within the indicated times before surgery. Have a history of substance or alcohol abuse and/or a positive result on drug screening. Have a positive test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) at the screening visit. Have dysphagia and/or cannot swallow study medication whole. Have a history of migraine or frequent headaches, seizures, or are currently taking anticonvulsants. Have previously participated in a clinical trial using COV795 or had a bunionectomy in the last 3 months. Received any investigational drugs or devices within 4 weeks prior to the screening visit. Other criteria as specified in the trial protocol.
Facility Information:
Facility Name
Trovare Clinical Research, Inc.
City
Bakersfield
State/Province
California
ZIP/Postal Code
93311
Country
United States
Facility Name
Lotus Clinical Research, LLC
City
Pasedena
State/Province
California
ZIP/Postal Code
91105
Country
United States
Facility Name
Chesapeake Research Group, LLC
City
Pasadena
State/Province
Maryland
ZIP/Postal Code
21122
Country
United States
Facility Name
Endeavor Clinical Trials, PA
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
Jean Brown Research, Inc.
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84124
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
25157951
Citation
Singla N, Barrett T, Sisk L, Kostenbader K, Young J. Assessment of the safety and efficacy of extended-release oxycodone/acetaminophen, for 14 days postsurgery. Curr Med Res Opin. 2014 Dec;30(12):2571-8. doi: 10.1185/03007995.2014.957824. Epub 2014 Oct 13.
Results Reference
derived
PubMed Identifier
24351079
Citation
Singla N, Barrett T, Sisk L, Kostenbader K, Young J, Giuliani M. A randomized, double-blind, placebo-controlled study of the efficacy and safety of MNK-795, a dual-layer, biphasic, immediate-release and extended-release combination analgesic for acute pain. Curr Med Res Opin. 2014 Mar;30(3):349-59. doi: 10.1185/03007995.2013.876979. Epub 2014 Jan 10.
Results Reference
derived

Learn more about this trial

Safety and Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain With an Open-label Extension

We'll reach out to this number within 24 hrs